| Filed On | Filing |
|---|---|
| 20 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders +2 more
The name of the Company is Damora Therapeutics, Inc. (the “Company”). |
| 17 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Damora Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders on June 17, 2026 (the “Annual Meeting”). The following proposals were submitted to the stockholders of the Company at the Annual Meeting, which are de... |
| 04 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 20 Apr 2026 |
8-K: Changes in Registrant's Certifying Accountant
We have read Item 4.01 of Form 8-K dated April 17, 2026 of Damora Therapeutics, Inc. and are in agreement with the statements contained in the paragraphs under (a) Dismissal of Independent Registered Public Accounting Firm therein. We ha... |
| 23 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
On behalf of the Board of Directors (the “Board”) of Galecto, Inc. (the “Company”), I am very pleased to offer you a position as President and Chief Executive Officer of the Company (“CEO”) and a member of the Board pursuant to this lett... |
| 10 Mar 2026 |
8-K: Results of Operations and Financial Condition; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders |
| 11 Feb 2026 |
8-K: Entry into a Material Definitive Agreement
Introductory. Galecto, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 14,473,685 shares of its common stock, par value $0.0000... |
| 10 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
TO THEAMENDED AND RESTATED CERTIFICATE OF INCORPORATIONOFGALECTO, INC. |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
Disclaimers The information contained in this presentation has been prepared by Galecto Inc. and its affiliates (“Galecto” or the “Company”) and contains information pertaining to the business and operations of the Company. The informati... |
| 06 Jan 2026 |
8-K: Unregistered Sales of Equity Securities; Departure/Election of Directors or Officers; Compensation
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE O... |
| 10 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +4 more
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of November 10, 2025, by and among GALECTO, INC., a Delaware corporation (“Parent”), DAYLIGHT MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent ... |
| 20 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Galecto, Inc. (the “Company”) held its annual meeting (the “Annual Meeting”) of stockholders on June 18, 2025. The following proposals were submitted to the stockholders at the Annual Meeting: |
| 15 Oct 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
BOSTON, October 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler... |
| 07 Oct 2024 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +4 more
Appendix I - Officers, directors and stockholders of Buyer executing Buyer Stockholder Support Agreements |
| 18 Sep 2024 |
8-K: Other Events
On September 16, 2024, Galecto, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff determined that, from August 3... |
| 11 Sep 2024 |
8-K: Other Events
On August 29, 2023, the Company filed with the Secretary of State of the State of Delaware the Certificate of Amendment to effect a one-time reverse stock split of the Company’s common stock, at a ratio of 1-for-25 (the “Reverse Stock Sp... |
| 05 Sep 2024 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
TO THEAMENDED AND RESTATED CERTIFICATE OF INCORPORATIONOFGALECTO, INC. |
| 21 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
Galecto, Inc. (the “Company”) held its annual meeting (the “Annual Meeting”) of stockholders on June 20, 2024. The following proposals were submitted to the stockholders at the Annual Meeting: |
| 26 Mar 2024 |
8-K: Other Events
As previously disclosed, on September 27, 2023, Galecto, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company th... |
| 21 Dec 2023 |
8-K: Other Events
On December 21, 2023, Galecto, Inc. (the “Company,” or “Galecto”) announced positive topline results from its Phase 2a MYLOX-1 trial of GB2064 for the treatment of myelofibrosis. The MYLOX-1 trial dosed a total of 18 myelofibrosis patien... |
Loading...